InMed Pharmaceuticals Inc. (OTCMKTS:IMLFF – Get Free Report) shares were up 0.3% on Wednesday . The stock traded as high as $3.23 and last traded at $3.17. Approximately 43,188 shares were traded during trading, an increase of 280% from the average daily volume of 11,369 shares. The stock had previously closed at $3.16.
InMed Pharmaceuticals Stock Performance
The firm’s 50 day moving average price is $4.18 and its two-hundred day moving average price is $2.24.
About InMed Pharmaceuticals
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain.
Further Reading
- Five stocks we like better than InMed Pharmaceuticals
- What is diluted earnings per share (Diluted EPS)?
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- What is Insider Trading? What You Can Learn from Insider Trading
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- What Are the FAANG Stocks and Are They Good Investments?
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
